Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edit functionality is currently unavailable.

Masayuki Hagiwara, Ph.D., M.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Li W, Zhang N, Jin C, Long MD, Rajabi H, Yasumizu Y, Fushimi A, Yamashita N, Hagiwara M, Zheng R, Wang J, Kui L, Singh H, Kharbanda S, Hu Q, Liu S, Kufe D. MUC1-C drives stemness in progression of colitis to colorectal cancer. JCI Insight. 2020 Jun 18; 5(12). PMID: 32427590.
    Citations:    
  2. Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D. Author Correction: MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020 Feb 24; 11(1):1095. PMID: 32094369.
    Citations:    
  3. Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020 01 17; 11(1):338. PMID: 31953400.
    Citations:    
  4. Matsumoto K, Niwa N, Hagiwara M, Kosaka T, Tanaka N, Takeda T, Morita S, Mizuno R, Shinojima T, Hara S, Asanuma H, Oya M. Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy. World J Urol. 2020 Jul; 38(7):1749-1756. PMID: 31559475.
    Citations:    
  5. Shigeta K, Kikuchi E, Abe T, Hagiwara M, Ogihara K, Anno T, Umeda K, Baba Y, Sanjo T, Shojo K, Mikami S, Mizuno R, Oya M. A Novel Risk-based Approach Simulating Oncological Surveillance After Radical Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2019 Aug 05. PMID: 31395480.
    Citations:    
  6. Kaneko G, Shirotake S, Nishimoto K, Miyazaki Y, Ito K, Ito Y, Hagiwara M, Kanao K, Nakagawa K, Momma T, Asano T, Tanaka N, Mizuno R, Oya M, Oyama M. Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy. Jpn J Clin Oncol. 2019 Aug 01; 49(8):780-785. PMID: 31063191.
    Citations:    
  7. Shigeta K, Kikuchi E, Abe T, Hagiwara M, Ogihara K, Anno T, Umeda K, Baba Y, Sanjo T, Shojo K, Mizuno R, Oya M. Long-Term Oncologic Outcomes of Laparoscopic Versus Open Radical Nephroureterectomy for Patients with T3N0M0 Upper Tract Urothelial Carcinoma: A Multicenter Cohort Study with Adjustment by Propensity Score Matching. Ann Surg Oncol. 2019 Oct; 26(11):3774-3781. PMID: 31313043.
    Citations:    
  8. Ogihara K, Kikuchi E, Okazaki S, Hagiwara M, Takeda T, Matsumoto K, Kosaka T, Mikami S, Saya H, Oya M. Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer. Cancer Sci. 2019 Apr; 110(4):1431-1441. PMID: 30719824.
    Citations:    
  9. Ito K, Masunaga A, Tanaka N, Mizuno R, Shirotake S, Yasumizu Y, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Momma T, Masuda T, Nakagawa K, Oyama M, Asano T, Oya M. Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma. Jpn J Clin Oncol. 2019 Jan 01; 49(1):69-76. PMID: 30407543.
    Citations:    Fields:    
  10. Yanai Y, Takeda T, Miyajima A, Matsumoto K, Hagiwara M, Mizuno R, Kikuchi E, Asanuma H, Oya M. Is transperitoneal laparoscopic radical nephrectomy suitable for patients with a history of abdominal surgery? Asian J Endosc Surg. 2019 Oct; 12(4):429-433. PMID: 30506839.
    Citations:    
  11. Hagiwara M, Kikuchi E, Tanaka N, Kosaka T, Mikami S, Saya H, Oya M. Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer. BMC Cancer. 2018 01 31; 18(1):113. PMID: 29385995.
    Citations:    
  12. Hagiuda J, Ishikawa H, Hagiwara M, Kono H, Nakagawa K, Oya M. Obstructive azoospermia caused by low ligation of varicocele: A case report. Syst Biol Reprod Med. 2017 Oct; 63(5):338-339. PMID: 28771041.
    Citations:    
  13. Shigeta K, Kikuchi E, Hagiwara M, Ando T, Mizuno R, Abe T, Mikami S, Miyajima A, Nakagawa K, Oya M. The Conditional Survival with Time of Intravesical Recurrence of Upper Tract Urothelial Carcinoma. J Urol. 2017 12; 198(6):1278-1285. PMID: 28634017.
    Citations:    
  14. Shigeta K, Kikuchi E, Hagiwara M, Ando T, Mizuno R, Miyajima A, Nakagawa K, Oya M. Prolonged pneumoperitoneum time is an independent risk factor for intravesical recurrence after laparoscopic radical nephroureterectomy in upper tract urothelial carcinoma. Surg Oncol. 2017 Mar; 26(1):73-79. PMID: 28317587.
    Citations:    
  15. Tanaka N, Mizuno R, Yasumizu Y, Ito K, Shirotake S, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model. Urol Oncol. 2017 02; 35(2):39.e19-39.e28. PMID: 27825515.
    Citations: 2     Fields:    Translation:HumansCells
  16. Ide H, Kikuchi E, Hagiwara M, Hayakawa N, Hongo H, Miyajima A, Oya M. Urinary pH Levels are Strongly Associated with Bladder Recurrence After Nephroureterectomy in Upper Tract Urothelial Carcinoma Patients with a Smoking History. Ann Surg Oncol. 2016 12; 23(Suppl 5):1029-1038. PMID: 27613550.
    Citations:    
  17. Hagiwara M, Kikuchi E, Kosaka T, Mikami S, Saya H, Oya M. Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality. Urol Oncol. 2016 08; 34(8):337.e19-26. PMID: 27133224.
    Citations:    
  18. Tanaka N, Mizuno R, Shirotake S, Ito K, Yasumizu Y, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M. Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings. Urol Oncol. 2016 07; 34(7):293.e17-25. PMID: 27040380.
    Citations:    Fields:    Translation:Humans
  19. Shirotake S, Yasumizu Y, Ito K, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Tanaka N, Mizuno R, Oya M. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2016 12; 14(6):e575-e583. PMID: 27102405.
    Citations: 1     Fields:    Translation:Humans
  20. Kobayashi H, Kikuchi E, Tanaka N, Shirotake S, Miyazaki Y, Ide H, Obata J, Hoshino K, Matsumoto K, Kaneko G, Hagiwara M, Kosaka T, Oyama M, Nakajima Y, Oya M. Patient age was an independent predictor of cancer-specific survival in male patients with upper tract urothelial carcinoma treated by radical nephroureterectomy. Jpn J Clin Oncol. 2016 06; 46(6):554-559. PMID: 26962241.
    Citations:    
  21. Tanaka N, Mizuno R, Ito K, Shirotake S, Yasumizu Y, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M. External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study. Eur Urol Focus. 2016 Aug; 2(3):303-309. PMID: 28723377.
    Citations:    Fields:    
  22. Katsui M, Kikuchi E, Yazawa S, Hagiwara M, Morita S, Shinoda K, Kosaka T, Mizuno R, Shinojima T, Asanuma H, Miyajima A, Oya M. [CLINICAL BACKGROUND ANALYSIS ABOUT TRANSURETHRAL ELECTROCOAGULATION]. Nihon Hinyokika Gakkai Zasshi. 2015 Oct; 106(4):255-63. PMID: 26717784.
    Citations:    
  23. Yuge K, Kikuchi E, Hagiwara M, Yasumizu Y, Tanaka N, Kosaka T, Miyajima A, Oya M. Nicotine Induces Tumor Growth and Chemoresistance through Activation of the PI3K/Akt/mTOR Pathway in Bladder Cancer. . 2015 Sep; 14(9):2112-20. PMID: 26184482.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  24. Shigeta K, Kikuchi E, Hagiwara M, Hattori S, Kaneko G, Hasegawa M, Takeda T, Jinzaki M, Akita H, Miyajima A, Nakagawa K, Oya M. Visceral to total obesity ratio and severe hydronephrosis are independently associated with prolonged pneumoperitoneum operative time in patients undergoing laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma. Springerplus. 2015; 4:290. PMID: 26120507.
    Citations: 1     
  25. Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, Kobayashi H, Kaneko G, Hagiwara M, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Hara S, Nakagawa K, Jinzaki M, Oya M. Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis. Eur Urol Focus. 2015 Aug; 1(1):54-63. PMID: 28723357.
    Citations:    
  26. Maeda T, Kikuchi E, Hasegawa M, Ishioka K, Hagiwara M, Miyazaki Y, Shinojima T, Miyajima A, Oya M. Solifenacin or mirabegron could improve persistent overactive bladder symptoms after dutasteride treatment in patients with benign prostatic hyperplasia. Urology. 2015 May; 85(5):1151-1155. PMID: 25770728.
    Citations: 1     Fields:    Translation:Humans
  27. Yuge K, Miyajima A, Jinzaki M, Kaneko G, Hagiwara M, Hasegawa M, Takeda T, Kikuchi E, Nakagawa K, Oya M. How does visceral obesity affect surgical performance in laparoscopic radical nephrectomy? Jpn J Clin Oncol. 2015 Apr; 45(4):373-7. PMID: 25637501.
    Citations: 2     Fields:    Translation:Humans
  28. Shirotake S, Kikuchi E, Tanaka N, Matsumoto K, Miyazaki Y, Kobayashi H, Ide H, Obata J, Hoshino K, Kaneko G, Hagiwara M, Kosaka T, Kanao K, Kodaira K, Hara S, Oyama M, Momma T, Miyajima A, Nakagawa K, Hasegawa S, Nakajima Y, Oya M. Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience. J Urol. 2015 Apr; 193(4):1122-8. PMID: 25444957.
    Citations:    
  29. Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, Kobayashi H, Kaneko G, Hagiwara M, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Hara S, Oyama M, Momma T, Nakajima Y, Jinzaki M, Oya M. A multi-institutional validation of the prognostic value of the neutrophil-to-lymphocyte ratio for upper tract urothelial carcinoma treated with radical nephroureterectomy. Ann Surg Oncol. 2014 Nov; 21(12):4041-8. PMID: 24912614.
    Citations:    
  30. Matsumoto K, Mizuno R, Tanaka N, Ide H, Hasegawa M, Ishida M, Hayakawa N, Yasumizu Y, Hagiwara M, Hara S, Kikuchi E, Miyajima A, Nakagawa K, Nakajima Y, Nakamura S, Nakashima J, Oya M. Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy. Med Oncol. 2014 Jul; 31(7):45. PMID: 24913809.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  31. Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Hayakawa N, Hagiwara M, Kosaka T, Oyama M, Miyajima A, Momma T, Nakagawa K, Jinzaki M, Hasegawa S, Nakajima Y, Oya M. Independent predictors for bladder outcomes after treatment of intravesical recurrence following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma. Ann Surg Oncol. 2014 Sep; 21(9):3151-8. PMID: 24682698.
    Citations:    
  32. Matsumoto K, Hagiwara M, Hayakawa N, Tanaka N, Ito Y, Maeda T, Ninomiya A, Nagata H, Nakamura S. Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: report of 52 cases and literature review. Asian Pac J Cancer Prev. 2014; 15(8):3645-9. PMID: 24870772.
    Citations:    
  33. Hagiwara M, Kikuchi E, Tanaka N, Matsumoto K, Ide H, Miyajima A, Masuda T, Nakamura S, Oya M. Impact of smoking status on bladder tumor recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. J Urol. 2013 Jun; 189(6):2062-8. PMID: 23328579.
    Citations: 9     Fields:    Translation:Humans
  34. Hagiwara M, Miyajima A, Hasegawa M, Jinzaki M, Kikuchi E, Nakagawa K, Oya M. Visceral obesity is a strong predictor of perioperative outcome in patients undergoing laparoscopic radical nephrectomy. BJU Int. 2012 Dec; 110(11 Pt C):E980-4. PMID: 22642302.
    Citations: 6     Fields:    Translation:Humans
  35. Hagiwara M, Miyajima A, Matsumoto K, Kikuchi E, Nakagawa K, Oya M. Benefit of laparoscopic radical nephrectomy in patients with a high BMI. Jpn J Clin Oncol. 2011 Mar; 41(3):400-4. PMID: 20926414.
    Citations:    
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Hagiwara's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (145)
Explore
_
Co-Authors (7)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.